SCHEMBL4512925

SCHEMBL4512925

CC(N)CNc1nc(-c2cc(F)c(F)cc2O)nc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 1/20 0.51
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
MAPT P10636 5/20 0.48
MAPK1 P28482 2/20 0.48
POLB P06746 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
GBA1 P04062 1/20 0.46
PIP4K2A P48426 1/20 0.46
PRKCI P41743 3/20 0.44
EGFR P00533 2/20 0.44
TLR7 Q9NYK1 1/20 0.44
ALDH1A1 P00352 2/20 0.43
HIF1A Q16665 1/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
HSD17B10 Q99714 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4512916 1.00 ACP1 (0.51) ACP1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4504618 0.91 ACP1 (0.49) ACP1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4504631 0.91 ACP1 (0.49) ACP1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4504624 0.91 ACP1 (0.49) ACP1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4521050 0.90 LMNA (0.47) ACP1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4521061 0.90 LMNA (0.47) ACP1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4521057 0.90 LMNA (0.47) ACP1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4513025 0.89 ACP1 (0.50) ACP1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4513028 0.89 ACP1 (0.50) ACP1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4513018 0.89 ACP1 (0.50) ACP1LMNASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE PKD2, PKD1, AADAT ACP1 282/4885LMNA 2132/4885SMN1; SMN2 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.